Revista da Sociedade Brasileira de Medicina Tropical (Jan 2020)

Characterization of adverse reactions to benznidazole in patients with Chagas disease in the Federal District, Brazil

  • Maria Katarine Costa Lucas Gontijo,
  • Hilda Maria Benevides da Silva de Arruda,
  • Elza Ferreira Noronha,
  • Maria Inês de Toledo

DOI
https://doi.org/10.1590/0037-8682-0150-2019
Journal volume & issue
Vol. 53

Abstract

Read online

Abstract INTRODUCTION: Benznidazole is used for treating Chagas disease (CD). This cross-sectional study aimed to characterize the adverse drug reactions (ADRs) of benznidazole at a public hospital in Brazil’s Federal District. METHODS: Medical records were analyzed and ADRs were categorized by type, intensity, seriousness, and causality. RESULTS: Of the 62 patients who started benznidazole treatment for CD, 41 (66%) presented with 105 ADRs; 23 (37%) discontinued the treatment. Most reactions were classified as probable (81%), severe (63%), serious (67%), and dose-dependent (56%). CONCLUSIONS: The high incidence of ADRs because of treatment withdrawal revealed the need for safer alternatives for CD treatment.

Keywords